Fluoroquinolones Up Risk for Severe Dysglycemia in DiabetesFluoroquinolones Up Risk for Severe Dysglycemia in Diabetes
Use of fluoroquinolones, in particular moxifloxacin, appears to increase the risk of severe blood glucose swings in patients with diabetes compared with the use of other classes of antibiotic. Medscape Medical News
Publication date: September–October 2020Source: Diabetes &Metabolic Syndrome: Clinical Research &Reviews, Volume 14, Issue 5Author(s): Abhinav Vepa, Joseph P. Bae, Faheem Ahmed, Manish Pareek, Kamlesh Khunti
Abstract Background/Objectives: To investigate the association between vitiligo and metabolic syndrome. Methods: A prospective cross-sectional study was conducted between 2014 and 2016. Study (n = 155) and control groups (n = 155) were evaluated for metabolic syndrome according to National Cholesterol Education Program Adult Treatment Panel III and the International Diabetes Federation criteria. Study group was divided into three groups according to their vitiligo area severity index and vitiligo disease activity score values (Group 1: 6.89 for VASI score, Group A: − 1-0, Group B: 1-2 and Group C: 3-4 for vitiligo di...
French pharmaceutical company Servier Laboratories is facing millions of euros in potential fines after a massive trial around a diabetes drug used as a diet pill
Publication date: 5 January 2021Source: Journal of Hazardous Materials, Volume 401Author(s): Man Cheng, Yun Zhou, Bin Wang, Ge Mu, Jixuan Ma, Min Zhou, Dongming Wang, Meng Yang, Limin Cao, Li xie, Xing Wang, Xiuquan Nie, LingLing Yu, Jing Yuan, Weihong Chen
(American Society for Biochemistry and Molecular Biology) Visualizing the age of insulin secreting granules in cells allowed researchers to investigate how cells' preference for secreting newer granules is disrupted in diabetes.
(Technical University of Munich (TUM)) The composition and function of bacteria in the human intestine -- the so-called gut microbiome -- changes as the day progresses. This was established by researchers based in Freising at ZIEL - Institute for Food&Health of the Technical University of Munich (TUM) with one of the largest studies related to microbiomes and diabetes comprising more than 4000 participants. These daily variations in the gut microbiome cease to exist in people suffering from type 2 diabetes.
(Institute for Quality and Efficiency in Health Care) First study on a treatment strategy using a proteomic analysis does not clarify which therapeutic consequence of the test could offer a benefit for people with diabetes and high blood pressure.